Secondary analysis of a placebo-controlled trial in early symptomatic Alzheimer's disease: donanemab slowed CDR-SB decline across baseline tau PET and plasma P-tau217 levels, with greater slowing at lower tau; modelled delay was 60% vs 17% for earlier vs later treatment.
Secondary analysis
Raket et al. Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial